Table 2.
Clinical Pseudomonas aeruginosa isolates evaluated.
| Strain no. | Origin of isolate |
Genotype | Meropenem |
Assays |
||||
|---|---|---|---|---|---|---|---|---|
| Country | Anatomical site | MIC (mg/L) | PCR | GES-LAMP | Carba-GES-LAMP | |||
| GES β-lactamase-producing strains | ||||||||
| AZPAE14831 | Argentina | RTIa | GES-1 | 0.5 | (S)d | (+) | (+) | (-) |
| AZPAE14948 | Argentina | IAIb | GES-5 | >32 | (R) | (+) | (+) | (+) |
| AZPAE13856 | India | Unknown | GES-7 | 0.5 | (S) | (+) | (+) | (-) |
| AZPAE13848 | India | Unknown | GES-9 | 0.25 | (S) | (+) | (+) | (-) |
| AZPAE13880 | Mexico | Unknown | OXA-2, GES-19, GES-20-like | >32 | (R) | (+) | (+) | (+) |
| Other β-lactamase-producing strains | ||||||||
| AZPAE13872 | Mexico | Unknown | IMP-15 | >32 | (R) | (-) | (-) | (-) |
| AZPAE13879 | Argentina | Unknown | VIM-11, OXA-17 | 16 | (R) | (-) | (-) | (-) |
| AZPAE14688 | Mexico | Unknown | IMP-18 | >32 | (R) | (-) | (-) | (-) |
| AZPAE14719 | Colombia | RTI | KPC-2 | >32 | (R) | (-) | (-) | (-) |
| AZPAE14720 | Colombia | UTIc | OXA-2, KPC-2 | >32 | (R) | (-) | (-) | (-) |
| AZPAE14822 | Brazil | IAI | OXA-56 | 8 | (R) | (-) | (-) | (-) |
| AZPAE14862 | India | UTI | IMP-13 | 2 | (S) | (-) | (-) | (-) |
| AZPAE14900 | India | IAI | OXA-10, VEB-like, VIM-5 | 16 | (R) | (-) | (-) | (-) |
| AZPAE15029 | France | RTI | VIM-2, OXA-4 | >32 | (R) | (-) | (-) | (-) |
aRespiratory tract infections; bUrinary tract infections, cIntra-abdominal infections. d (S), susceptible; (R), resistant.